AU
UK
CA
NZ
IND
US
Last update at 2026-06-11T10:43:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Interim Report January-September 2023
Tue 24 Oct 23, 06:00 AMNomination Committee of XVIVO Perfusion AB (publ)
Fri 29 Sep 23, 04:20 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 38.56M | 199.95M | 94.52M | 22.31M | 6.67M |
| Minority interest | - | - | - | - | - |
| Net income | 25.16M | 172.18M | 91.82M | 18.43M | 8.15M |
| Selling general administrative | 78.14M | 95.79M | 76.94M | 62.58M | 55.69M |
| Selling and marketing expenses | 298.94M | 283.98M | 232.26M | 152.40M | 97.69M |
| Gross profit | 533.50M | 616.41M | 445.11M | 296.96M | 188.28M |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | 82.93M | 205.55M | 4.19M | 12.85M | -18.74200M |
| Ebitda | 153.14M | 272.97M | 35.05M | 21.70M | -11.70000M |
| Depreciation and amortization | 70.21M | 67.42M | 30.86M | 8.85M | 7.04M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 93.02M | 88.35M | 4.19M | 12.85M | -18.74200M |
| Other operating expenses | 719.15M | 734.06M | 593.36M | 394.50M | 251.44M |
| Interest expense | 44.37M | 5.60M | 1.19M | - | 0.00000M |
| Tax provision | - | - | - | - | -1.48700M |
| Interest income | - | - | - | - | 25.16M |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 13.40M | 27.77M | 2.70M | 3.89M | 1.49M |
| Total revenue | 812.16M | 822.41M | 597.54M | 415.29M | 258.39M |
| Total operating expenses | 440.48M | 528.06M | 440.92M | 276.16M | 181.34M |
| Cost of revenue | 278.67M | 206.00M | 152.43M | 118.34M | 70.11M |
| Total other income expense net | -54.45600M | 111.59M | 90.33M | 9.46M | 25.41M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | - | - | - | - |
| Net income applicable to common shares | - | - | - | 18.43M | 8.15M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2374.11M | 2402.74M | 2195.61M | 1733.08M | 1542.60M |
| Intangible assets | 840.29M | 724.80M | 628.97M | 8.48M | 8.66M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 38.03M | 40.59M | 19.90M | 19.21M |
| Total liab | 260.65M | 245.97M | 250.57M | 302.95M | 257.15M |
| Total stockholder equity | 2113.46M | 2156.78M | 1945.05M | 1430.14M | 1285.45M |
| Deferred long term liab | - | - | - | 544.51M | 456.55M |
| Other current liab | - | 115.21M | 72.60M | 96.43M | 83.07M |
| Common stock | 0.82M | 0.81M | 0.81M | 0.76M | 0.75M |
| Capital stock | - | - | - | - | - |
| Retained earnings | 316.90M | 291.75M | 119.57M | 27.75M | 9.28M |
| Other liab | - | - | - | 163.60M | 151.10M |
| Good will | 610.06M | 682.48M | 591.39M | 625.32M | 460.23M |
| Other assets | - | - | - | 583.78M | 498.72M |
| Cash | 292.09M | 415.52M | 545.79M | 246.54M | 398.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 119.38M | 177.51M | 134.49M | 134.90M | 104.52M |
| Current deferred revenue | - | - | 3.69M | - | - |
| Net debt | -54.20500M | -381.47800M | -514.35100M | -246.54500M | -398.69600M |
| Short term debt | 11.56M | 10.92M | 10.27M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 237.89M | 34.04M | 31.44M | - | 1.52M |
| Other stockholder equity | 1785.08M | 1772.03M | 1763.78M | 1401.62M | 1275.42M |
| Property plant equipment | - | - | - | 47.58M | 26.30M |
| Total current assets | 688.21M | 813.08M | 826.40M | 467.51M | 547.53M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 796.33M | 816.56M |
| Short term investments | - | - | 300.00M | - | - |
| Net receivables | 147.66M | 132.12M | 98.13M | 94.50M | 52.04M |
| Long term debt | - | - | - | - | 1.52M |
| Inventory | 248.46M | 227.41M | 141.60M | 106.57M | 77.59M |
| Accounts payable | 107.82M | 39.45M | 36.05M | 38.47M | 21.45M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 10.65M | 92.19M | 60.88M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 0.90M | 598.50M | -681.79400M | -496.34200M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1685.90M | 1589.67M | 1369.21M | 681.79M | 496.34M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | - | - | -0.40100M |
| Change to liabilities | - | - | - | 11.02M | 0.00000M |
| Total cashflows from investing activities | -258.41000M | -243.81400M | -161.61900M | -197.62400M | -187.70300M |
| Net borrowings | - | - | - | - | -10.74200M |
| Total cash from financing activities | 72.25M | -10.90200M | 418.55M | -6.84200M | 234.61M |
| Change to operating activities | - | - | - | - | -1.12200M |
| Net income | 25.16M | 199.95M | 91.82M | 18.43M | 8.15M |
| Change in cash | -123.43000M | -130.56700M | 299.54M | -152.15100M | 44.46M |
| Begin period cash flow | 415.52M | 546.09M | 246.54M | 398.70M | 354.24M |
| End period cash flow | 292.09M | 415.52M | 546.09M | 246.54M | 398.70M |
| Total cash from operating activities | 101.07M | 111.29M | 46.29M | 27.86M | -12.05900M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 70.21M | - | 30.86M | 15.23M | 11.88M |
| Other cashflows from investing activities | -258.41000M | -193.45500M | -100.92400M | 0.78M | -0.40300M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -37.94000M | -77.51500M | -33.48100M | -6.32500M | -13.80200M |
| Change to account receivables | 8.79M | -17.77200M | -25.03400M | -26.86000M | -8.29400M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 72.25M | -10.90200M | -10.70300M | 0.45M | 245.35M |
| Change to netincome | - | - | - | -10.57100M | -29.25000M |
| Capital expenditures | 101.07M | 193.15M | 43.02M | 18.18M | 10.19M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -68.72900M | -79.11500M | -39.22400M | -33.18500M | -22.09600M |
| Stock based compensation | - | - | 2.30M | 6.69M | 2.60M |
| Other non cash items | 74.42M | -9.54300M | -39.47400M | 20.70M | -12.60100M |
| Free cash flow | - | -81.86300M | -97.64900M | 9.67M | -22.25300M |
Sector: Industry:
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) |
|---|---|---|---|---|---|---|
| 0RKL Xvivo Perfusion AB |
1.00 0.37% | 272.40 | 10.61 | - | 8.20 | - |
| 0R15 SoftBank Group Corp. |
-982.0 13.93% | 6066.00 | - | - | - | - |
| 0R1E Nintendo Co. Ltd. |
-283.0 3.73% | 7297.00 | - | - | - | - |
| 0M69 OTP Bank Nyrt |
28000.15 222.40% | 40590.15 | - | - | - | - |
| 0LC3 Synchrony Financial |
-1.295 1.83% | 69.36 | 0.09 | - | 4.97 | - |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Gemenskapens gata 9, Mölndal, Sweden, 431 53
| Name | Title | Year Born |
|---|---|---|
| Mr. Christoffer Rosenblad | Chief Exec. Officer | 1975 |
| Mr. Kristoffer Nordstrom | CFO & Investor Relations | 1985 |
| Ms. Lena Hagman B.Sc. | Chief Operating Officer | 1965 |
| Dr. Magnus Nilsson Ph.D. | Sr. Advisor | 1956 |
| Ms. Katrin Gisselfalt Ph.D. | Global Quality Assurance & Regulatory Affairs Director | 1969 |
| Mr. Andreas Wallinder M.D., Ph.D. | Chief Medical Officer | 1977 |
| Mr. Johan Holmstrom | Chief Commercial Officer | 1970 |
| Ms. Charlotte Walldal | Global R&D director | 1967 |
| Jaya Tiwari | VP Clinical and Regulatory Affairs | NA |
| Mr. Christer de Flon | Mang. | 1949 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...